133 related articles for article (PubMed ID: 11706114)
1. Rapid infusion of intravenous immune globulin in patients with neuromuscular disorders.
Grillo JA; Gorson KC; Ropper AH; Lewis J; Weinstein R
Neurology; 2001 Nov; 57(9):1699-701. PubMed ID: 11706114
[TBL] [Abstract][Full Text] [Related]
2. Identification and comparison of adverse events for preparations of IVIG in patients with neuromuscular diseases.
Nadeau JO; Bhibhatbhan A; McDougall D; Toth C
Clin Neurol Neurosurg; 2010 Jul; 112(6):467-9. PubMed ID: 20227821
[TBL] [Abstract][Full Text] [Related]
3. Intravenous immunoglobulin therapy for neuromuscular disorders.
Ross MA
Semin Neurol; 2007 Sep; 27(4):340-6. PubMed ID: 17701871
[TBL] [Abstract][Full Text] [Related]
4. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.
Gürcan HM; Ahmed AR
Ann Pharmacother; 2007 Oct; 41(10):1604-10. PubMed ID: 17785614
[TBL] [Abstract][Full Text] [Related]
5. Safety of intravenous immune globulin in an outpatient setting for patients with neuromuscular disease.
Waheed W; Ayer GA; Jadoo CL; Badger GJ; Aboukhatwa M; Brannagan TH; Tandan R
Muscle Nerve; 2019 Nov; 60(5):528-537. PubMed ID: 31443119
[TBL] [Abstract][Full Text] [Related]
6. A Retrospective Observational Study of Adverse Reactions Associated With Intravenous Immunoglobulin Infusion.
Kato H; Hayashi M; Ohashi W; Yamaguchi T; Tanaka S; Kozono A; Gao S; Katai A; Niwa R; Matsuo T; Ishiyama K; Ando T; Ogawa M; Nakayama T
Front Immunol; 2021; 12():740517. PubMed ID: 34603326
[TBL] [Abstract][Full Text] [Related]
7. Safety of intravenous immunoglobulin in the elderly treated for a dysimmune neuromuscular disease.
Lozeron P; Not A; Theaudin M; Denier C; Masnou P; Sarov M; Adam C; Cauquil C; Adams D
Muscle Nerve; 2016 May; 53(5):683-9. PubMed ID: 26467654
[TBL] [Abstract][Full Text] [Related]
8. Rapid infusion of intravenous immunoglobulin in patients with neuromuscular diseases.
Gomperts ED; Darr F
Neurology; 2002 May; 58(9):1444. PubMed ID: 12011310
[No Abstract] [Full Text] [Related]
9. Factors associated with headache in intravenous immunoglobulin treatment for neurological diseases.
Graf J; Ingwersen J; Lepka K; Albrecht P; Hartung HP; Ringelstein M; Aktas O
Acta Neurol Scand; 2019 Oct; 140(4):290-295. PubMed ID: 31269227
[TBL] [Abstract][Full Text] [Related]
10. Hemolytic anemia following high dose intravenous immunoglobulin in patients with chronic neurological disorders.
Markvardsen LH; Christiansen I; Harbo T; Jakobsen J
Eur J Neurol; 2014; 21(1):147-52. PubMed ID: 24180709
[TBL] [Abstract][Full Text] [Related]
11. Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee.
Donofrio PD; Berger A; Brannagan TH; Bromberg MB; Howard JF; Latov N; Quick A; Tandan R
Muscle Nerve; 2009 Nov; 40(5):890-900. PubMed ID: 19768755
[TBL] [Abstract][Full Text] [Related]
12. Mitigating the risk of COVID-19 exposure by transitioning from clinic-based to home-based immune globulin infusion.
Perreault S; Schiffer M; Clinchy-Jarmoszko V; Bocchetta N; Barbarotta L; Abdelghany O; Foss F; Huntington S; Seropian S; Isufi I
Am J Health Syst Pharm; 2021 Jun; 78(12):1112-1117. PubMed ID: 33617630
[TBL] [Abstract][Full Text] [Related]
13. Safety of liquid intravenous immunoglobulin for neuroimmunologic disorders in the home setting: a retrospective analysis of 1085 infusions.
Rigas M; Tandan R; Sterling RJ
J Clin Neuromuscul Dis; 2008 Dec; 10(2):52-5. PubMed ID: 19169090
[TBL] [Abstract][Full Text] [Related]
14. Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases.
Tufan F; Kamali S; Erer B; Gul A; Inanc M; Ocal L; Konice M; Aral O
Clin Rheumatol; 2007 Nov; 26(11):1913-5. PubMed ID: 17636363
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Subcutaneous Immunoglobulin in the Treatment of Neuromuscular Disorders.
Salameh JS; Deeb W; Burawski L; Wright S; Souayah N
J Clin Neuromuscul Dis; 2016 Mar; 17(3):110-9. PubMed ID: 26905911
[TBL] [Abstract][Full Text] [Related]
16. Long-term day-case treatment of peripheral neuromuscular disease with intravenous immunoglobulin: the practice of a regional day-case service in Preston, Lancashire.
Nixon J; McHugh C; Jones S
Clin Med (Lond); 2013 Aug; 13(4):358-61. PubMed ID: 23908504
[TBL] [Abstract][Full Text] [Related]
17. The safety profile of home infusion of intravenous immunoglobulin in patients with neuroimmunologic disorders.
Souayah N; Hasan A; Khan HM; Yacoub HA; Jafri M
J Clin Neuromuscul Dis; 2011 Jun; 12 Suppl 4():S1-10. PubMed ID: 22361589
[TBL] [Abstract][Full Text] [Related]
18. Comparison of IVIg 5% Versus 10% in hematological patients with a secondary immunodeficiency disorder.
Van Ham J; Janssens A; Raddoux J; Raets E; Delforge M
Acta Clin Belg; 2021 Feb; 76(1):49-52. PubMed ID: 31422766
[No Abstract] [Full Text] [Related]
19. The current place of high-dose immunoglobulins in the treatment of neuromuscular disorders.
van der Meché FG; van Doorn PA
Muscle Nerve; 1997 Feb; 20(2):136-47. PubMed ID: 9040650
[TBL] [Abstract][Full Text] [Related]
20. Intravenous immune globulin in neuromuscular disorders.
Gupta S
West J Med; 1997 Nov; 167(5):349-50. PubMed ID: 9392991
[No Abstract] [Full Text] [Related]
[Next] [New Search]
